- Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A phase I/II trial of D,L-MEthadone and mFOLFOX6 in treatment of advanced colorectal cancer (MEFOX)
This study is testing a new combination of treatments for advanced bowel cancer. It's looking at whether adding a drug called D,L-methadone to standard chemotherapy (mFOLFOX6) can help control the cancer, and how safe it is.
For: Patients with advanced · histologically confirmed · metastatic colorectal carcinomaGermany - Ongoing, recruitingTherapeutic use (Phase IV)
SURVIVAL ANALYSIS AFTER NEOADJUVANT TREATMENT IN RESECTABLE PANCREATIC CANCER WITH RISK FACTORS
This study looks at how long people with a certain type of pancreatic cancer live after receiving treatment. It specifically focuses on real-world experiences with common chemotherapy drugs before surgery.
For: Resectable pancreatic adenocarcinoma with risk factorsSpain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression FORTITUDE-101)
This study looks at a new drug, bemarituzumab, for advanced stomach or gullet cancer that hasn't been treated before. It aims to see if adding bemarituzumab to standard chemotherapy helps people live longer and improves their quality of life compared to chemotherapy alone.
For: Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b overexpressionPoland · Hungary · Latvia - RecruitingPHASE3
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
This study compares two treatments for advanced left-sided bowel cancer that hasn't spread. It looks at how long people stay disease-free when given a new drug called amivantamab with chemotherapy, versus a standard drug called cetuximab with chemotherapy.
For: Colorectal NeoplasmsUnited States · Belgium · Brazil - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA)
This study compares a new cell therapy (Tisagenlecleucel) with standard treatments for adults with an aggressive type of lymphoma that has come back or not responded to previous therapy. Researchers want to see which treatment is better at stopping the cancer from growing.
For: Adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphomaNetherlands · Spain · Norway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab Plus Gemcitabine Plus Oxaliplatin (R- GEMOX) Versus R- GEMOX Alone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This study looks at a new drug combination, Polivy plus R-GEMOX, for adults with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to previous treatments. It compares this combination to R-GEMOX alone, checking for safety and how well it works.
For: Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)Italy · Germany · Spain - RecruitingPHASE3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
This study is testing new combinations of medicines (sonesitatug vedotin, rilvegostomig, and capecitabine) for advanced stomach, gastroesophageal junction, or oesophageal cancers. It aims to see how well they work and if they are safe for people whose cancer has a specific marker called Claudin18.2.
For: Gastric Cancer · Gastroesophageal Junction Adenocarcinoma · Esophageal CancerUnited States · Australia · Austria - Active not recruitingPHASE3
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
This study looks at a new drug, zanidatamab, combined with chemotherapy, and sometimes another drug called tislelizumab. It aims to see if this treatment works better and is safer than standard chemotherapy for advanced stomach and gullet cancers that have HER2.
For: Gastric Neoplasms · Gastroesophageal Adenocarcinoma · Esophageal AdenocarcinomaArgentina · Australia · Belgium - Active not recruitingPHASE3
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
This study looks at a new medicine called zolbetuximab, combined with chemotherapy, for adults with advanced stomach cancer. It aims to see if this combination works better than chemotherapy alone to stop the cancer from getting worse.
For: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer · Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer · Metastatic Gastric Adenocarcinoma or CancerUnited States · Australia · Belgium - Active not recruitingPHASE3
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
This study looks at new drug combinations for advanced bowel cancer that has spread and has a specific gene change (BRAF). It compares these new combinations with standard chemotherapy to see which works best for people who haven't had treatment for their spread cancer.
For: NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE1
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
This study is for adults with advanced cancers in places like the lungs or stomach that are hard to treat or have spread. It's testing a new drug, PF-08046050, to see if it's safe and helps shrink these cancers, sometimes with other medicines.
For: Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Stomach NeoplasmsUnited States · Canada · China - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
This study looks at a new drug, pembrolizumab, for certain types of oesophageal cancer. It compares giving pembrolizumab alongside standard chemotherapy and radiotherapy with giving a dummy drug (placebo) with the same standard treatment. We want to see if the new drug can help people live longer or prevent the cancer from coming back.
For: Esophageal Squamous Cell Carcinoma (ESCC) · Gastroesophageal Junction Carcinoma (GEJC) · Esophageal Adenocarcinoma (EAC)United States · Argentina · Belgium - Active not recruitingPHASE3
Paediatric Hepatic International Tumour Trial
This study, called PHITT, is for children and young people up to 30 years old with liver cancers called hepatoblastoma (HB) and hepatocellular carcinoma (HCC). It aims to find better ways to treat these cancers by using tailored treatments and studying them closely.
For: Hepatoblastoma · Carcinoma, HepatocellularAustria · Belgium · Czechia - RecruitingPHASE3
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
This study looks at a new way to give a cancer drug called tislelizumab for advanced stomach cancer. We're comparing injections under the skin to drips into a vein, alongside usual chemotherapy. We want to see if the injection works just as well and is easier for patients.
For: Metastatic Gastric Adenocarcinoma · Gastroesophageal Junction AdenocarcinomaUnited States · Argentina · Austria - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
For: CancerUnited States · Argentina · Australia - RecruitingPHASE2
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
This study looks at new treatments for advanced stomach or oesophageal cancer with a specific protein called HER2. We're testing a new drug, trastuzumab deruxtecan, by itself or with other common cancer medicines to see if it's safe and effective.
For: Gastric CancerUnited States · Brazil · Canada - Active not recruitingPHASE3
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This study looks at a new drug, glofitamab, combined with standard chemotherapy (GemOx) for people with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to previous treatments. It compares this new combination to a standard treatment.
For: Diffuse Large B-cell LymphomaUnited States · Australia · Belgium - RecruitingPHASE3
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
This study looks at a new drug, calderasib, for advanced bowel cancer with a specific genetic change (KRAS G12C). Researchers want to see if adding calderasib to standard treatments helps people live longer without their cancer growing.
For: Colon Adenocarcinoma · Rectal AdenocarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE3
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
This study is testing a new combination of medicines with chemotherapy for some upper gut cancers that have spread and can't be removed by surgery. It aims to see if the new combination works better than current treatments.
For: Advanced Upper Gastrointestinal Tract AdenocarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
This study looks at a new drug, zolbetuximab, combined with chemotherapy for advanced stomach or food pipe cancer. It aims to see if this combination works better than chemotherapy alone for people with a specific protein in their cancer.
For: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer · Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer · Metastatic Gastric Adenocarcinoma or CancerUnited States · Argentina · Canada - Active not recruitingPHASE3
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This study looks at new treatments for Diffuse Large B-Cell Lymphoma (DLBCL) that has come back or not responded to previous treatment. It compares a new drug called epcoritamab with standard treatments to see which works best and is safest.
For: Diffuse Large B-Cell LymphomaUnited States · Argentina · Australia - AuthorisedPhase II and Phase III (Integrated)
TOTAL NEOADJUVANT TREATMENT WITHOUT SURGERY FOR LOCALLY ADVANCED RECTAL CANCER: PROSPECTIVE CLINICAL TRIAL TO ASSESS TUMOR COMPLETE RESPONSE, CIRCULATING TUMOR GENETIC AND EPIGENETIC BIOMARKERS, AND STROMAL TRANSCRIPTOME TO INTERPRET CLINICAL OUTCOME (NO-CUT TRIAL)
This study looks at a new way to treat locally advanced rectal cancer in adults. It's testing if a combination of chemotherapy drugs, without surgery, can effectively remove the tumour. Researchers will also check biological markers in the body to understand how well treatments work.
For: Adenocarcinoma of the medium/lower rectum in Stage II (cT3-4 N0) or Stage III (cT1-4Italy - AuthorisedTherapeutic confirmatory (Phase III)
Efficacy of the use of neoadjuvant with/without hyperthermic intraperitoneal chemotherapy in the treatment of locally advanced colon cancer: A phase III multi-arm, randomized and controlled clinical trial (FOXHIPECT4)
This study is testing different ways to treat advanced colon or upper rectal cancer. It looks at adding a special heated chemotherapy wash to standard treatment during surgery to see if it helps people live longer without the cancer coming back. The aim is to find the best treatment.
Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
ATTENUATION – A multicenter randomized phase II study of the efficacy and safety de-escalation versus standard adjuvant chemotherapy in patients with low risk localized gastroesophageal adenocarcinoma (study PRODIGE/FRENCH 39)
This study looks at a new way to treat stomach and gullet cancer after surgery. Half of the patients get less chemotherapy, and the other half get the usual amount. We want to see if less treatment is just as good, safer, and helps people feel better.
For: Low risk of disease recurrence · defined by the following criteria: - Absence of lymph node involvement (ypN0) · assessed on a min. of 15 lymph nodes andFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA 25) – Substudy B – Relapsed/Refractory Richter Transformation (RT)
This study looks at a new cell therapy called Tecartus for adults with a type of blood cancer called Richter Transformation that has come back or not responded to previous treatments. It aims to see how well it works and if it's safe.
For: Relapsed/refractory Richter Transformation (RT)France · Germany · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA 25) – Substudy C – Relapsed/Refractory Burkitt Lymphoma (BL)
This study is looking at a new treatment called Tecartus for adults in the UK with a specific type of blood cancer called Burkitt Lymphoma. It's for patients whose cancer has come back or hasn't responded to previous treatments. Researchers want to see how well Tecartus works.
For: Relapsed/Refractory Burkitt Lymphoma (BL)Netherlands · France · Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma
This study is looking at new ways to treat advanced oesophageal cancer. We're testing a combination of new drugs and chemotherapy to see if it works better than standard treatments, with a focus on safety and how long people live while on the treatment.
For: Esophageal CarcinomaSpain · Hungary · France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE 811)
This study looks at a new combination of medicines for a type of stomach or food pipe cancer that has spread. It compares adding the drug pembrolizumab to standard treatment to see if it helps patients live longer without their cancer growing.
For: Gastric or gastroesophageal junction (GEJ) adenocarcinomaIreland · France · Spain - Ongoing, recruitingPhase III and phase IV (Integrated)
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)
This study looks at new drug combinations for advanced stomach or food pipe cancer. It compares a new mix of drugs (Lenvatinib, Pembrolizumab, and chemotherapy) against the usual treatment to see which works best and is safest for patients.
For: Advanced/Metastatic Gastroesophageal AdenocarcinomaSpain · Belgium · Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Multicenter, Open-label, Phase 2 Basket Study of MK‑7684A, a Co formation of Vibostolimab (MK‑7684) With Pembrolizumab (MK‑3475), With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (KEYVIBE 005)
This study, called KEYVIBE 005, is testing a new combination of medicines (MK-7684A, which includes vibostolimab and pembrolizumab) for people with advanced solid tumours. Researchers want to see how well this new treatment shrinks tumours and stops them from growing, either alone or with other cancer therapies.
For: Advanced solid tumorsSpain · Italy · Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102)
This study is for people with advanced stomach or gut cancer that has a specific genetic marker called FGFR2b. It tests a new drug, bemarituzumab, combined with usual treatments (chemotherapy and nivolumab) to see if it works better than usual treatments alone.
For: Gastric and Gastroesophageal Junction Cancer With FGFR2b OverexpressionGermany · Poland · Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with HER2 negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (KEYNOTE-859)
This study is testing a new medicine, pembrolizumab (Keytruda), alongside standard chemotherapy for advanced stomach or food pipe cancer. It aims to see if this combination helps people live longer compared to chemotherapy alone, especially for cancers that don’t have too much of a protein called HER2.
For: Gastric and gastric esophageal junction (GEJ) adenocarcinomaDenmark · France · Ireland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)
This study is looking at a new treatment for stomach cancer and cancer where the food pipe joins the stomach. It's comparing a drug called pembrolizumab combined with chemotherapy against chemotherapy alone, to see if it helps patients live longer and stops the cancer from coming back.
For: Gastric and gastroesophageal junction (GEJ) adenocarcinomaPoland · Belgium · Italy - Ongoing, recruitingPhase II and Phase III (Integrated)
PRODIGE 51 - GASTFOX: Phase III randomised trial evaluating FOLFOX with or without DOCETAXEL (TFOX) as 1st line chemotherapy for locally advanced or metastatic oesophago-gastric adenocarcinoma
This study is looking at a new way to treat advanced stomach and gullet cancer. It compares a standard chemotherapy treatment with the same treatment plus an extra drug to see if it helps people live longer without their cancer growing. It involves adults with this type of cancer.
For: Locally advanced or metastatic oesogastric adenocarcinomaFrance - AuthorisedTherapeutic confirmatory (Phase III)
Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair (ATOMIC)
This study is looking at a new treatment for stage 3 bowel cancer that has a specific genetic feature. It compares standard chemotherapy with chemotherapy plus a new drug called atezolizumab (Tecentriq) to see if the new combination helps people live longer without their cancer coming back.
For: stage III colon adenocarcinoma with deficient MMRGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
PRODIGE 54 SAMCO : MULTICENTER RANDOMIZED PHASE II STUDY COMPARING THE EFFECTIVENESS AND TOLERANCE OF AVELUMAB VERSUS STANDARD 2nd LINE TREATMENT CHEMOTHERAPY IN PATIENTS WITH COLORECTAL METASTATIC CANCER WITH MICROSATELLITE INSTABILITY (MSI)
This study compares a new drug, avelumab, with standard chemotherapy for advanced bowel cancer that has spread and has specific genetic changes (microsatellite instability). We want to see if avelumab can stop the cancer from growing for longer.
For: COLORECTAL METASTATIC CANCER WITH MICROSATELLITE INSTABILITYFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
Neoadjuvant Chemotherapy followed by Pre-operative Chemoradiation and Consolidation Chemotherapy before Surgery in High Risk Rectal Cancer: Multicentric Phase II Study
This study is testing a new way to treat advanced bowel cancer that affects the rectum. It involves a combination of strong medicines given before surgery to see if it can help the cancer disappear completely. We're hoping this approach will lead to better results for patients.
For: High Risk Rectal CancerItaly - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer
This study is looking at new ways to treat advanced bowel cancer (colorectal cancer that has spread). It combines existing treatments with new drugs to see if they work better together. The aim is to find safer and more effective options for patients.
For: Metastatic colorectal cancerFrance · Italy · Spain - AuthorisedTherapeutic confirmatory (Phase III)
An open labelled phase III adjuvant trial of disease-free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine-based chemotherapy by standard clinical criteria or by a transcriptomic treatment specific stratification signature (ESPAC-6)
This study is looking at different chemotherapy treatments for people in the UK who have had pancreatic cancer removed by surgery. It aims to find out which treatment works best to stop the cancer from coming back by comparing standard care with a new way of choosing treatment based on genetic information.
For: Resected pancreatic ductal adenocarcinomaGermany · Sweden - AuthorisedTherapeutic exploratory (Phase II)
Phase II study of Durvalumab (MEDI4736) plus Total Neoadjuvant Therapy (TNT) in locally advanced rectal cancer (The DUREC trial)
This study is looking at a new way to treat locally advanced rectal cancer. It combines standard chemotherapy and radiotherapy with a new drug called Durvalumab to see if this combination causes the cancer to completely disappear before surgery.
For: Locally advanced rectal cancerSpain - RecruitingPHASE2
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
This study looks at new treatments for advanced stomach or gullet cancer. It combines a new drug, ABBV-400, with existing chemotherapy and another new drug, Budigalimab. We want to find the safest and most effective dose and see how well it works.
For: Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma · Esophageal AdenocarcinomaUnited States · Belgium · Canada - RecruitingPHASE2, PHASE3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
This study is testing a new medicine, zilovertamab vedotin (ZV), combined with standard treatments for a type of lymphoma called diffuse large B-cell lymphoma (DLBCL). It's for people whose lymphoma has come back or hasn't responded to previous treatments.
For: DLBCL · Diffuse Large B-Cell LymphomaUnited States · Argentina · Australia - Active not recruitingPHASE3
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This study looks at a new drug combination for adults with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or hasn't responded to previous treatment. It compares the new drug with standard treatment to see if it works better.
For: Relapsed Diffuse Large B-Cell Lymphoma · Refractory Diffuse Large B-Cell LymphomaUnited States · Argentina · Belgium - Active not recruitingPHASE3
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
This study looks at new drug combinations for advanced bowel cancer that has spread. It compares nivolumab alone, nivolumab with ipilimumab, and standard chemotherapy to see which works best for patients whose cancer has specific features (dMMR/MSI-H).
For: Metastatic Colorectal CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
This study tested new drug combinations for advanced oesophageal cancer. It looked at pembrolizumab with lenvatinib and chemotherapy, versus pembrolizumab and chemotherapy, to see which worked best and was safest. The study has now stopped, with no safety concerns being the reason.
For: Metastatic Esophageal Squamous Cell CarcinomaUnited States · Argentina · Canada - RecruitingPHASE3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
This study is testing if a new combination of medicines, including tucatinib, works better than current treatments for people with advanced HER2-positive bowel cancer. It also looks at side effects. Participants will be randomly assigned to receive either the new combination or standard care.
For: Colorectal NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
This study looks at new drug combinations for stomach (gastric) or food pipe (GEJ) cancer that has a specific marker called HER2. It compares different treatment mixes to see which works best and is safest for advanced cancer.
For: HER2-positive Gastric Cancer · Gastroesophageal Junction AdenocarcinomaUnited States · Argentina · Australia - AuthorisedTherapeutic use (Phase IV)
A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL) - ARIEL-ENGIC trial
This study looks at new ways to treat advanced bowel cancer that has specific genetic features. Researchers want to see if combining existing treatments can shrink tumours early and help people live longer, while also improving their quality of life.
For: advanced colorectal cancer with wild-type RAS and right primary tumour location (right-PTL)Italy · Germany · Spain - AuthorisedTherapeutic confirmatory (Phase III)
NACRE 2_Randomized phase III study evaluating two treatment strategies for locally advanced rectal cancer in patients ≥75 years old
This study is looking at different ways to treat advanced bowel cancer in people over 75, comparing standard surgery with a plan that tries to avoid major surgery while still aiming for a good outcome. It wants to see which approach works best.
For: Patients ≥75 years old with cT3/T4 rectal adenocarcinoma eligible to radiotherapy · FOLFOX chemotherapy and total mesorectal excision (TME) surgeryFrance - AuthorisedTherapeutic confirmatory (Phase III)
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)
This study is looking at a new treatment called ivonescimab, given with standard chemotherapy (FOLFOX), for bowel cancer that has spread. We compare it to another treatment (bevacizumab) also with FOLFOX, to see which works best at stopping the cancer from growing.
For: Metastatic colorectal cancerBelgium · Italy · Spain